Shares of Twist Bioscience Corp (TWST) plunged 12.16% in Monday's pre-market session, despite the company reporting better-than-expected fiscal Q1 2025 results. The synthetic DNA manufacturer's stock suffered a sharp sell-off as investors expressed concerns over the company's forward guidance.
For the first quarter ended December 2024, Twist Bioscience reported revenue of $88.7 million, surpassing Wall Street expectations of $86.9 million. The company also posted a narrower loss of $0.53 per share, beating analysts' estimates of a $0.62 per share loss.
However, Twist Bioscience's outlook failed to impress investors. The company projected Q2 2025 revenue in the range of $91 million to $93 million, while full-year 2025 revenue is expected to be between $372 million and $379 million. These forecasts seemingly fell short of market expectations, triggering a sell-off in TWST's shares.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.